OpGen

OpGen Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of OpGen (OPGN) as of Oct 19, 2026 is -130.76. In the previous year, Cash Conversion Cycle (CCC) was -2,692.73 — a change of -95.14% (higher).

Cash Conversion Cycle

-130.76

YoY

-95.14%

Last updated:

Cash Conversion Cycle (CCC) of OpGen is 2025 -130.76 . Cash Conversion Cycle (CCC) of OpGen was 2024 -2,692.73 . It decreases by -95.14% higher compared to the previous year.

The OpGen Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
-166.98 USD
Jan 1, 2019
-71.14 USD
Jan 1, 2020
20.26 USD
Jan 1, 2021
90.68 USD
Jan 1, 2022
170.50 USD
Jan 1, 2023
-0.53 USD
Jan 1, 2024
-2,692.73 USD
Jan 1, 2025
-130.76 USD
The OpGen Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-130.76-95.14%
-2,692.73+507,712.14%
-0.53-100.31%
170.50+88.02%
90.68+347.54%
20.26-128.48%
-71.14-57.40%
-166.98+57.35%
-106.12-45.96%
-196.36-26.10%
-265.72+2.79%
-258.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen Inc is a biotechnology company based in Gaithersburg, Maryland, operating within the Health Care sector. The company went public on May 5, 2015, with ticker OPGN and ISIN US68373L5057. It currently employs three people. OpGen develops molecular information solutions focused on combating infectious diseases in global healthcare settings. The company's technology involves DNA tests and bioinformatics to address antibiotic resistance, assisting healthcare providers in managing patient care decisions and monitoring the spread of multidrug-resistant microorganisms. Its solutions aim to guide clinicians with information about life-threatening infections and help manage patient outcomes. The company's website is http://opgen.com/. OpGen is engaged in creating tools to help protect the hospital biome through customized screening and surveillance. The firm markets its high-resolution DNA tests under the Acuitas trade name. The company has a global network of customers and partners. OpGen does not provide specific details on its product names beyond Acuitas, and no additional financial figures or historical data are available in the provided information. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Cash Conversion Cycle (CCC) of OpGen is -130.76 in 2025.

Cash Conversion Cycle (CCC) of OpGen changed from -2,692.73 to -130.76, representing a -95.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) OpGen since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s OpGen with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — OpGen

All Key Metrics — OpGen